KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 14 years of Deferred Taxes data on record, last reported at -$63.3 million in Q4 2025.

  • For Q4 2025, Deferred Taxes fell 2588.28% year-over-year to -$63.3 million; the TTM value through Dec 2025 reached -$445.0 million, down 113.59%, while the annual FY2025 figure was -$445.0 million, 113.59% down from the prior year.
  • Deferred Taxes reached -$63.3 million in Q4 2025 per JAZZ's latest filing, up from -$271.4 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $190.7 million in Q2 2021 and bottomed at -$271.4 million in Q3 2025.
  • Average Deferred Taxes over 5 years is -$56.8 million, with a median of -$64.5 million recorded in 2022.
  • Peak YoY movement for Deferred Taxes: skyrocketed 1114.78% in 2021, then tumbled 2588.28% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at -$27.4 million in 2021, then tumbled by 430.67% to -$145.4 million in 2022, then surged by 75.31% to -$35.9 million in 2023, then surged by 93.44% to -$2.4 million in 2024, then crashed by 2588.28% to -$63.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were -$63.3 million in Q4 2025, -$271.4 million in Q3 2025, and -$66.4 million in Q2 2025.